Opendata, web and dolomites

LSDiASD

Leveraging Small Demethylase inhibitors for Autism Spectrum Disorder

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LSDiASD project word cloud

Explore the words cloud of the LSDiASD project. It provides you a very rough idea of what is the project "LSDiASD" about.

turn    underlying    generalizable    disability    23    treatment    autism    comprising       asd    erc    duplication    penetrant    plan    lsd1    wish    alterations    language    region    diseaseavatars    7q11    proof    business    variations    inhibition    opposite    gtf2i    point    efficacy    yield    disorder    few    inhibitors    hemideletion    represses    modifier    behavioural    individuals    chromosome    stereotyped    cnv    points    clinical    28    function    diseases    sociability    splitting    discovered    industrial    mouse    convergent    competence    found    syndromes    worldwide    behaviours    spectrum    vivo    transcription    associating    core    featuring    intellectual    deficits    lysine    chromatin    aggregate    hope    genes    broadly    autistic    gene    lesions    paradigmatic    despite    7dup    convergence    prerequisites    vulnerable    caused    genetic    consolidator    consistency    dependent    inroads    traits    facto    williams    dissect    models    impairment    inhibitor    syndrome    prevalent    phenotypes    cognitive    400    therapeutic    circuits    rescues    symmetrically    rescuing    neurodevelopmental    remarkable    rare    advancing    causing    26    grounds    demethylase    recapitulating    de    dosage    causative    symptoms    copy    neuronal   

Project "LSDiASD" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITA DEGLI STUDI DI MILANO 

Organization address
address: Via Festa Del Perdono 7
city: MILANO
postcode: 20122
website: www.unimi.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 145˙250 €
 EC max contribution 145˙250 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-PoC
 Funding Scheme ERC-POC
 Starting year 2016
 Duration (year-month-day) from 2016-11-01   to  2018-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITA DEGLI STUDI DI MILANO IT (MILANO) coordinator 107˙750.00
2    TTFACTOR SRL IT (MILANO) participant 37˙500.00

Map

 Project objective

Duplication of chromosome region 7q11.23 (7Dup), comprising 26-28 genes, is one of best characterized copy number variations (CNV) causing Autism Spectrum Disorder (ASD), a very prevalent neurodevelopmental condition affecting more than 1% individuals worldwide, and for which no effective treatment is available. Despite the remarkable consistency of core ASD symptoms (impairment in language and sociability along with stereotyped behaviours), over 400 causative genetic lesions have been thus far identified for ASD, splitting it de facto into an aggregate of rare and highly penetrant genetic diseases. In turn, the convergence of symptoms grounds the hope that few paradigmatic syndromes may yield generalizable therapeutic inroads across the autistic spectrum. 7Dup is a case in point since it is symmetrically opposite to Williams Syndrome, a condition caused by 7q11.23 hemideletion and featuring symmetrically opposite phenotypes in language and sociability, thus offering unique opportunities to dissect the dosage-vulnerable circuits that affect language competence and sociability. Specifically, convergent evidence points to transcription factor GTF2I as the key gene underlying the cognitive/behavioural traits of 7Dup. Within my ERC-Consolidator project DISEASEAVATARS we discovered that increased GTF2I dosage represses key genes involved in intellectual disability, autism and neuronal function by associating with lysine demethylase 1 (LSD1), a key chromatin modifier, and found that LSD1 inhibition rescues GTF2I-dependent alterations. Therefore, we now wish to establish in vivo proof of concept for the efficacy of novel LSD1 inhibitors in rescuing cognitive-behavioural deficits in relevant ASD mouse models recapitulating GTF2I CNV, developing an adequate business plan and industrial partnerships as prerequisites for advancing the most effective LSD1 inhibitor towards pre-clinical development for 7Dup and ASD more broadly.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LSDIASD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LSDIASD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

ENUF (2019)

Evaluation of Novel Ultra-Fast selective III-V Epitaxy

Read More  

DeCoCt (2019)

Knowledge based design of complex synthetic microbial communities for plant protection

Read More  

REAL (2019)

Rights and Egalitarianism

Read More